Oral supplementation of medium-chain fatty acids during the dry period supports the neutrophil viability of peripartum dairy cows

A randomised clinical trial was conducted to explore the effect of orally supplemented medium-chain fatty acids (MCFA) to heifers and cows starting 6-8 weeks prior to expected calving date on blood and milk polymorphonuclear neutrophilic leucocyte (PMNL) apoptosis between 1 and 3 d in milk (DIM). The effects of MCFA-supplementation on the likelihood of intramammary infections (IMI) in early lactation, and test-day somatic cell count (SCC) and average daily milk yield (MY) during the first 4 months of lactation were evaluated as well. Twenty-two animals were included of which half were orally supplemented with MCFA starting 6-8 weeks prior to calving and half served as non-supplemented controls. The PMNL viability in both blood and milk was quantified using dual-colour flow cytometry with fluorescein-labelled annexin and propidium iodide. In non-supplemented animals, % blood PMNL apoptosis significantly increased between start of supplementation and early lactation, reflecting a potential reduction in innate immune capacity, whereas this was not true in the MCFA-supplemented animals. Similar results were seen in milk PMNL apoptosis. Overall, the % apoptotic milk PMNL between 1 and 3 DIM was significantly lower in the MCFA-supplemented group compared with the non-supplemented group. There was no substantial effect of oral MCFA-supplementation on the likelihood of quarter IMI nor on the composite test-day milk SCC or average daily MY. In conclusion, oral MCFA-supplementation starting 6-8 weeks before expected calving date supported the blood and milk neutrophil viability in early lactating dairy cows. Still, this was not reflected in an improvement of udder health nor MY in early and later lactation. The results should trigger research to further unravel the mechanisms behind the observed immunomodulating effect, and the potential relevance for the cows' performances throughout lactation

Abordagem alternativa para o manejo da mastite – Como prevenir e controlar a mastite sem antibióticos?

Mastitis affects a high proportion of dairy cows throughout the world and is one of the greater problems faced by the dairy industry today. The disease is still a major cause of economic loss on a dairy farm. Mastitis poses not only negative consequences for the dairy farmer but also for the dairy industry as a number of issues threaten the reputation of milk as a healthy product from healthy animals. The use of antimicrobials is one of those concerns and threats. Antimicrobial usage on dairy farms is most often related to udder health as most medicines are used in prevention and control of mastitis. Antimicrobials remain vital for treatment of bacterial infections in dairy cattle, but in light of the upcoming debate instigated by the potential link between the use of antimicrobial products in animal husbandry and the development of antimicrobial resistance in both animal and human pathogens, there is an urgent need for innovation and alternatives to antibiotic therapy for mastitis treatment and control. Alternative approaches include vaccination, probiotics or beneficial microorganisms and inhibitory substances, immunomodulation, bacteriophages, homeopathy, and plant-derived inhibitory substances, yet only when scientifically-proven evidence is available indicating these alternatives are effective.A mastite ocorre em uma alta proporção de vacas leiteiras em todo o mundo e é um dos grandes problemas que atinge a indústria leiteira. A doença ainda é uma das maiores causas de perdas econômicas das granjas leiteiras. A mastite não tem apenas consequências negativas para os fazendeiros, mas atinge também a indústria leiteira, particularmente pela expectativa de que o leite deve ser um produto saudável produzido por animais saudáveis. O uso de antimicrobianos é uma grande preocupação. O emprego de antimicrobianos nas granjas leiteiras está frequentemente relacionado com a saúde do úbere uma vez que a maioria dos medicamentos são usados na prevenção e controle da mastite. Os antimicrobianos ainda são vitais para o tratamento das infecções bacterianas do gado leiteiro, mas na atualidade há um grande questionamento para a ligação potencial entre o uso de produtos antimicrobianos no manejo animal e o desenvolvimento de resistência antimicrobiana tanto de patógenos de animais como de humanos, há portanto a necessidade urgente da introdução de alternativas para o tratamento e controle da mastitecom antibióticos. As possibilidades incluem vacinação, probióticos ou microorganismos benéficos e substâncias inibidoras, imunomodulação, bacteriófagos, homeopatia, fitoterápicos inibidores. Contudo todos esses procedimentos necessitam ser cientificamente provadas para demonstrar que são alternativas realmente efetivos

Coagulase-negative staphylococci: contagious or environmental?: outline of two ongoing studies

C

Fecal non-aureus Staphylococci are a potential cause of bovine intramammary infection

The presence of non-aureus staphylococci (NAS) in bovine rectal feces has recently been described. Similar to other mastitis causing pathogens, shedding of NAS in the environment could result in intramammary infection. The objective of this study was to investigate whether NAS strains present in feces can cause intramammary infection, likely via teat apex colonization. During a cross-sectional study in 5 dairy herds, samples were collected from the habitats quarter milk, teat apices, and rectal feces from 25%, 10%, and 25% of the lactating cows, respectively, with a cow serving as the source of one type of sample only. Samples from clinical mastitis cases were continuously collected during the 1-year study period as well. The 6 most prevalent NAS species, Staphylococcus (S.) chromogenes, S. cohnii, S. devriesei, S. equorum, S. haemolyticus, and S. hominis, were further subtyped by random amplification of polymorphic deoxyribonucleic acid polymerase chain reaction (RAPD-PCR), when the same NAS species was present in the same herd in the three habitats. For S. chromogenes, S. cohnii, S. devriesei, and S. haemolyticus, the same RAPD type was found in rectal feces, teat apices, and quarter milk, indicating that fecal NAS can infect the mammary gland. For S. hominis and S. equorum, we were unable to confirm the presence of the same RAPD types in the three habitats

Associations between CXCR1 polymorphisms and pathogen-specific incidence rate of clinical mastitis, test-day somatic cell count, and test-day milk yield

The CXCR1 gene plays an important role in the innate immunity of the bovine mammary gland. Associations between single nucleotide polymorphisms (SNP) CXCR1c.735C>G and c.980A>G and udder health have been identified before in small populations. A fluorescent multiprobe PCR assay was designed specifically and validated to genotype both SNP simultaneously in a reliable and cost-effective manner. In total, 3,106 cows from 50 commercial Flemish dairy herds were genotyped using this assay. Associations between genotype and detailed phenotypic data, including pathogen-specific incidence rate of clinical mastitis (IRCM), test-day somatic cell count, and test-day milk yield (MY) were analyzed. Staphylococcus aureus IRCM tended to associate with SNP c.735C>G. Cows with genotype c.735GG had lower Staph. aureus IRCM compared with cows with genotype c.735CC (rate ratio = 0.35, 95% confidence interval = 0.14-0.90). Additionally, a parity-specific association between Staph. aureus IRCM and SNP c.980A>G was detected. Heifers with genotype c.980GG had a lower Staph. aureus IRCM compared with heifers with genotype c.980AG (rate ratio = 0.15, 95% confidence interval = 0.04-0.56). Differences were less pronounced in multiparous cows. Associations between CXCR1 genotype and somatic cell count were not detected. However, MY was associated with SNP c.735C>G. Cows with genotype c.735GG out-produced cows with genotype c.735CC by 0.8 kg of milk/d. Results provide a basis for further research on the relation between CXCR1 polymorphism and pathogen-specific mastitis resistance and MY

Antimicrobial consumption on dairy herds and its association with antimicrobial inhibition zone diameters of non-aureus staphylococci and Staphylococcus aureus isolated from subclinical mastitis

The main objectives of this study were to quantify the consumption of antimicrobials on a convenience sample of dairy herds and to determine the association between herd-level antimicrobial consumption and inhibition zone diameters (IZD) of non-aureus staphylococci and Staphylococcus aureus isolates from subclinical mastitis cases. Also, the association between the IZD of non-aureus staphylococci and Staph. aureus isolates within a herd was studied. Antimicrobial consumption data on 56 Flemish dairy farms were obtained between 2013 and 2014 by so-called garbage can audits and expressed as antimicrobial treatment incidence (ATI), with the unit of ATI being the number of defined daily doses animal (DDDA) used per 1,000 cow-days. The average total ATI in adult dairy cattle for all active substances was 18.73 DDDA per 1,000 cow-days and ranged from 6.28 to 42.13 DDDA between herds. The ATI of critically important (for human health) antimicrobials was 6.91 DDDA per 1,000 cow-days; that is, 37% of total antimicrobial consumption. The average ATI for intramammary therapy of (sub) clinical mastitis, intramammary dry-cow therapy, and systemically administered therapy was 5.20, 6.70, and 6.73 DDDA, respectively. The IZD of 239 non-aureus staphylococci and 88 Staph. aureus isolates originating from milk samples from cows with subclinical mastitis collected on selected dairy herds were determined using Kirby-Bauer disk diffusion and ranged between 6 and 42 mm. Because only a limited number of clinical breakpoints (Clinical and Laboratory Standards Institute) and epidemiological cut-off values (European Committee on Antimicrobial Susceptibility Testing) are available for mastitis-causing bacteria in bovine, IZD were used as a proxy for antimicrobial resistance. Inhibition zone diameters of non-aureus staphylococci for cefquinome, a critically important beta-lactam antibiotic, were negatively associated with the ATI of critically important beta-lactam for systemically administered therapy and positively with the ATI for intramammary therapy of (sub) clinical mastitis of critically important beta-lactam antimicrobials. Only for neomycin was a positive association between the IZD of non-aureus staphylococci and Staph. aureus isolates within the same herd observed